Медицинская радиология и радиационная безопасность. 2026. Том 71. № 5
DOI:10.33266/1024-6177-2026-71-5-33-39
Л. Алхаддад1, С.В. Леонов2, А.Н. Осипов2, 3
ОПУХОЛЕВЫЕ СТВОЛОВЫЕ КЛЕТКИ И ИХ ВОЗМОЖНАЯ РОЛЬ В НЕЭФФЕКТИВНОСТИ ЛУЧЕВОЙ ТЕРАПИИ
1 Университет Дамаска, Сирия, Дамаск
2 Московский физико-технический институт (Национальный исследовательский университет), Долгопрудный
3 Федеральный медицинский биофизический центр им. А.И. Бурназяна ФМБА России, Москва
Контактное лицо: Андреян Николаевич Осипов, e-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.
СОДЕРЖАНИЕ
Введение
Опухолевые стволовые клетки и их возможная роль в возникновении и прогрессировании опухолей
Перекрестные взаимодействия между опухолевыми стволовыми клетками и их нишами
Влияние эптителиально-мезенхимального перехода
Заключение
Ключевые слова: опухолевые стволовые клетки, онкологические заболевания, радиорезистентность, ионизирующие излучение, лучевая терапия
Для цитирования: Алхаддад Л., Леонов С.В., Осипов А.Н. Опухолевые стволовые клетки и их возможная роль в неэффективности лучевой терапии // Медицинская радиология и радиационная безопасность. 2026. Т. 71. № 5. С. 33–39. DOI:10.33266/1024-6177-2026-71-5-33-39
Список литературы
1.Eyler C.E., Rich J.N. Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis. Journal of Clinical Oncology. 2008;26;17:2839-45. Doi: 10.1200/JCO.2007.15.1829.
2.Fujiwara T., Bandi M., Nitta M., Ivanova E.V., Bronson R.T., Pellman D. Cytokinesis Failure Generating Tetraploids Promotes Tumorigenesis in p53-Null Cells. Nature. 2005;437;7061:1043-7. Doi: 10.1038/nature04217.
3.Замулаева И.А., Матчук О.Н., Селиванова Е.И., Андреев В.Г., Липунов Н.М., Макаренко С.А. и др. Увеличение количества опухолевых стволовых клеток под воздействием редкоионизирующего излучения // Радиационная биология. Радиоэкология. 2014. Т.54. №3. С. 256-264 [Zamulayeva I.A., Matchuk O.N., Selivanova Ye.I., Andreyev V.G., Lipunov N.M., Makarenko S.A., et al. Increase in the Number of Tumor Stem Cells under the Influence of Rare-Ionizing Radiation. Radiatsionnaya Biologiya. Radioekologiya = Radiation Biology. Radioecology. 2014;54;3:256–64 (In Russ)]. Doi: 10.7868/S0869803114030187.
4.Snijder B., Pelkmans L. Origins of Regulated Cell-to-Cell Variability. Nature Reviews Molecular Cell Biology. 2011;12;2:119-25. Doi: 10.1038/nrm3044.
5.Inda M.M., Bonavia R., Mukasa A., Narita Y., Sah D.W., Vandenberg S., et al. Tumor Heterogeneity is an Active Process Maintained by a Mutant EGFR-Induced Cytokine Circuit in Glioblastoma. Genes & Development. 2010;24;16:1731-45. Doi: 10.1101/gad.1890510.
6.Heppner G.H. Tumor Heterogeneity. Cancer Research. 1984;44;6:2259-65.
7.McQuerry J.A., Chang J.T., Bowtell D.D.L., Cohen A., Bild A.H. Mechanisms and Clinical Implications of Tumor Heterogeneity and Convergence on Recurrent Phenotypes. Journal of Molecular Medicine. 2017;95;11:1167-78. Doi: 10.1007/s00109-017-1587-4.
8.Visvader J.E. Cells of Origin in Cancer. Nature. 2011;469;7330:314-22. Doi: 10.1038/nature09781.
9.Lim Z.F., Ma P.C. Emerging Insights of Tumor Heterogeneity and Drug Resistance Mechanisms in Lung Cancer Targeted Therapy. Journal of Hematology & Oncology. 2019;12;1:134. Doi: 10.1186/s13045-019-0818-2.
10.Rich J.N. Cancer Stem Cells: Understanding Tumor Hierarchy and Heterogeneity. Medicine. 2016;95;1 Suppl 1:S2-S7. Doi: 10.1097/MD.0000000000004764.
11.Puhr M., Hoefer J., Schafer G., Erb H.H., Oh S.J., Klocker H., et al. Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205. The American Journal of Pathology. 2012;181;6:2188-201. Doi: 10.1016/j.ajpath.2012.08.011.
12.Alhaddad L., Osipov A.N., Leonov S. The Molecular and Cellular Strategies of Glioblastoma and Non-Small-Cell Lung Cancer Cells Conferring Radioresistance. International Journal of Molecular Sciences. 2022;23;21. Doi: 10.3390/ijms232113577.
13.Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and Expansion of the Tumorigenic Lung Cancer Stem Cell Population. Cell Death and Differentiation. 2008;15;3:504-14. Doi: 10.1038/sj.cdd.4402283.
14.Kendall S.E., Najbauer J., Johnston H.F., Metz M.Z., Li S., Bowers M., et al. Neural Stem Cell Targeting of Glioma is Dependent on Phosphoinositide 3-Kinase Signaling. Stem Cells. 2008;26;6:1575-86. Doi: 10.1634/stemcells.2007-0887.
15.Hamburger A.W., Salmon S.E. Primary Bioassay of Human Tumor Stem Cells. Science. 1977;197;4302:461-3. Doi: 10.1126/science.560061.
16.Han J., Won M., Kim J.H., Jung E., Min K., Jangili P., et al. Cancer Stem Cell-Targeted Bio-Imaging and Chemotherapeutic Perspective. Chemical Society Reviews. 2020;49;22:7856-78. Doi: 10.1039/d0cs00379d.
17.Alkon N., Ivanova A., Frolova E., Chumakov S. Cancer Stem Cells as Therapeutic Targets. Genes and Cells. 2018;13;2:25–34.
18.Clarke M.F., Fuller M. Stem Cells and Cancer: Two Faces of Eve. Cell. 2006;124;6:1111-5. Doi: 10.1016/j.cell.2006.03.011.
19.Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem Cells, Cancer, and Cancer Stem Cells. Nature. 2001;414;6859:105-11. Doi: 10.1038/35102167.
20.Liu Y., Yang M., Luo J., Zhou H. Radiotherapy Targeting Cancer Stem Cells «Awakens» them to Induce Tumour Relapse and Metastasis in Oral Cancer. International Journal of Oral Science. 2020;12;1:19. Doi: 10.1038/s41368-020-00087-0.
21.Chang L., Graham P., Hao J., Ni J., Deng J., Bucci J., et al. Cancer Stem Cells and Signaling Pathways in Radioresistance. Oncotarget. 2016;7;10:11002-17. Doi: 10.18632/oncotarget.6760.
22.Mirantes C., Espinosa I., Ferrer I., Dolcet X., Prat J., Matias-Guiu X. Epithelial-to-Mesenchymal Transition and Stem Cells in Endometrial Cancer. Human Pathology. 2013;44;10:1973-81. Doi: 10.1016/j.humpath.2013.04.009.
23.Пучинская М.В. Маркеры стволовых опухолевых клеток и их прогностическое значение // Архив патологии. 2016. Т.78. №2. С. 47–54 [Puchinskaya M.V. Cancer Stem Cell Markers and their Prognostic Value. Arkhiv Patologii = Russian Journal of Archive of Patology. 2016;78;2:47-54 (In Russ.)]. Doi: 10.17116/patol201678247-54.
24.Kong Y., Yoshida S., Saito Y., Doi T., Nagatoshi Y., Fukata M., et al. CD34+CD38+CD19+ as Well as CD34+CD38-CD19+ Cells are Leukemia-Initiating Cells with Self-Renewal Capacity in Human B-Precursor ALL. Leukemia. 2008;22;6:1207-13. Doi: 10.1038/leu.2008.83.
25.Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a Cancer Stem Cell in Human Brain Tumors. Cancer Research. 2003;63;18:5821-8.
26.Pustovalova M, Blokhina T, Alhaddad L, Chigasova A, Chuprov-Netochin R, Veviorskiy A, et al. CD44+ and CD133+ Non-Small Cell Lung Cancer Cells Exhibit DNA Damage Response Pathways and Dormant Polyploid Giant Cancer Cell Enrichment Relating to Their p53 Status. International Journal of Molecular Sciences. 2022;23;9. Doi: 10.3390/ijms23094922.
27.Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., et al. Isolation and in vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties. Cancer Research. 2005;65;13:5506-11. Doi: 10.1158/0008-5472.CAN-05-0626.
28.Pustovalova M., Alhaddad L., Blokhina T., Smetanina N., Chigasova A., Chuprov-Netochin R., et al. The CD44high Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status. International Journal of Molecular Sciences. 2021;22;5:2369. Doi: 10.3390/ijms22052369.
29.Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective Identification of Tumorigenic Prostate Cancer Stem Cells. Cancer Research. 2005;65;23:10946-51. Doi: 10.1158/0008-5472.CAN-05-2018.
30.Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and Expansion of Human Colon-Cancer-Initiating Cells. Nature. 2007;445;7123:111-5. Doi: 10.1038/nature05384.
31.Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., et al. A Distinct “Side Population” of Cells with High drug Efflux Capacity in Human Tumor Cells. Proceedings of the National Academy of Sciences of the United States of America. 2004;101;39:14228-33. Doi: 10.1073/pnas.0400067101.
32.Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., et al. Aldehyde Dehydrogenase 1 is a Tumor Stem Cell-Associated Marker in Lung Cancer. Molecular Cancer Research. 2009;7;3:330-8. Doi: 10.1158/1541-7786.MCR-08-0393.
33.Tirino V., Camerlingo R., Franco R., Malanga D., La Rocca A., Viglietto G., et al. The Role of CD133 in the Identification and Characterisation of Tumour-Initiating Cells in Non-Small-Cell Lung Cancer. European Journal of Cardio-Thoracic Surgery. 2009;36;3:446-53. Doi: 10.1016/j.ejcts.2009.03.063.
34.Huang Z., Cheng L., Guryanova O.A., Wu Q., Bao S. Cancer Stem Cells in Glioblastoma--Molecular Signaling and Therapeutic Targeting. Protein & Cell. 2010;1;7:638-55. Doi: 10.1007/s13238-010-0078-y.
35.Gilbert C.A., Ross A.H. Glioma Stem Cells: Cell Culture, Markers and Targets for New Combination Therapies. Cancer Stem Cells Theories and Practice. Rijeka, IntechOpen, 2011. P. 3-22.
36.Cole M.F., Johnstone S.E., Newman J.J., Kagey M.H., Young R.A. Tcf3 is an Integral Component of the Core Regulatory Circuitry of Embryonic Stem Cells. Genes & Development. 2008;22;6:746-55. Doi: 10.1101/gad.1642408.
37.Hu Q., Zhang L., Wen J., Wang S., Li M., Feng R., et al. The EGF Receptor-Sox2-EGF Receptor Feedback Loop Positively Regulates the self-Renewal of Neural Precursor Cells. Stem Cells. 2010;28;2:279-86. Doi: 10.1002/stem.246.
38.Ikushima H., Todo T., Ino Y., Takahashi M., Miyazawa K., Miyazono K. Autocrine TGF-Beta Signaling Maintains Tumorigenicity of Glioma-Initiating Cells Through SRY-Related HMG-Box Factors. Cell Stem Cell. 2009;5;5:504-14. Doi: 10.1016/j.stem.2009.08.018.
39.Marson A., Foreman R., Chevalier B., Bilodeau S., Kahn M., Young R.A., et al. Wnt Signaling Promotes Reprogramming of Somatic Cells to Pluripotency. Cell Stem Cell. 2008;3;2:132-5. Doi: 10.1016/j.stem.2008.06.019.
40.Po A., Ferretti E., Miele E., De Smaele E., Paganelli A., Canettieri G., et al. Hedgehog Controls Neural Stem Cells through p53-Independent Regulation of Nanog. The EMBO Journal. 2010;29;15:2646-58. Doi: 10.1038/emboj.2010.131.
41.Song I.S., Jeong Y.J., Han J. Mitochondrial Metabolism in Cancer Stem Cells: a Therapeutic Target for Colon Cancer. BMB Reports. 2015;48;10:539-40. Doi: 10.5483/bmbrep.2015.48.10.179.
42.Johannessen T.C., Bjerkvig R., Tysnes B.B. DNA Repair and Cancer Stem-Like Cells--Potential Partners in Glioma drug Resistance? Cancer Treatment Reviews. 2008;34;6:558-67. Doi: 10.1016/j.ctrv.2008.03.125.
43.Al-Hajj M., Becker M.W., Wicha M., Weissman I., Clarke M.F. Therapeutic Implications of Cancer Stem Cells. Current Opinion in Genetics & Development. 2004;14;1:43-7. Doi: 10.1016/j.gde.2003.11.007.
44.Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., et al. Cancerous Stem Cells Can Arise from Pediatric Brain Tumors. Proceedings of the National Academy of Sciences of the United States of America. 2003;100;25:15178-83. Doi: 10.1073/pnas.2036535100.
45.Lee S.Y., Jeong E.K., Ju M.K., Jeon H.M., Kim M.Y., Kim C.H., et al. Induction of Metastasis, Cancer Stem Cell Phenotype, and Oncogenic Metabolism in Cancer Cells by Ionizing Radiation. Molecular Cancer. 2017;16;1:10. Doi: 10.1186/s12943-016-0577-4.
46.Никифорова З.Н., Кудрявцев И.А., Арноцкая Н.Е., Брюховецкий И.С., Шевченко В.Е. Опухолевые стволовые клетки мультиформной глиобластомы // Успехи молекулярной онкологии. 2016. Т.3. №2. С. 26–33. [Nikiforova Z.N., Kudryavtsev I.A., Arnotskaya N.Ye., Bryukhovetskiy I.S., Shevchenko V.Ye. Tumor Stem Cells of Glioblastoma Multiforme. Uspekhi Molekulyarnoy Onkologii = Advances in Molecular Oncology. 2016;3;2:26-33 (In Russ.)].
47.Oskarsson T., Batlle E., Massague J. Metastatic Stem Cells: Sources, Niches, and Vital Pathways. Cell Stem Cell. 2014;14;3:306-21. Doi: 10.1016/j.stem.2014.02.002.
48.Ye J., Wu D., Wu P., Chen Z., Huang J. The Cancer Stem Cell Niche: Cross Talk between Cancer Stem Cells and Their Microenvironment. Tumour Biology. 2014;35;5:3945-51. Doi: 10.1007/s13277-013-1561-x.
49.Plaks V., Kong N., Werb Z. The Cancer Stem Cell Niche: how Essential is the Niche in Regulating Stemness of Tumor Cells? Cell Stem Cell. 2015;16;3:225-38. Doi: 10.1016/j.stem.2015.02.015.
50.Pozdnyakov D., Shuvalov O., Barlev N., Mittenberg A. Transcription Factor ZEB1: Post-Transcriptional Regulation of its Activity in Human Breast Carcinomas. Cytology. 2020;62;1:3-15.
51.Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell. 2008;133;4:704-15. Doi: 10.1016/j.cell.2008.03.027.
52.Kotiyal S., Bhattacharya S. Breast Cancer Stem Cells, EMT and Therapeutic Targets. Biochemical and Biophysical Research Communications. 2014;453;1:112-6. Doi: 10.1016/j.bbrc.2014.09.069.
53.Dezso Z., Oestreicher J., Weaver A., Santiago S., Agoulnik S., Chow J., et al. Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells. PloS One. 2014;9;8:e106131. Doi: 10.1371/journal.pone.0106131.
54.Kalluri R., Weinberg R.A. The Basics of Epithelial-Mesenchymal Transition. The Journal of Clinical Investigation. 2009;119;6:1420-8. Doi: 10.1172/JCI39104.
55.Caramel J., Papadogeorgakis E., Hill L., Browne G.J., Richard G., Wierinckx A., et al. A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma. Cancer Cell. 2013;24;4:466-80. Doi: 10.1016/j.ccr.2013.08.018.
56.Byers L.A., Diao L., Wang J., Saintigny P., Girard L., Peyton M., et al. An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research. 2013;19;1:279-90. Doi: 10.1158/1078-0432.CCR-12-1558.
57.Takebe N., Miele L., Harris P.J., Jeong W., Bando H., Kahn M., et al. Targeting Notch, Hedgehog, and Wnt Pathways in Cancer Stem Cells: Clinical Update. Nature Reviews Clinical Oncology. 2015;12;8:445-64. Doi: 10.1038/nrclinonc.2015.61.
58.Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., et al. Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research. 2009;69;14:5820-8. Doi: 10.1158/0008-5472.CAN-08-2819.
59.Gonzalez-Moreno O., Lecanda J., Green J.E., Segura V., Catena R., Serrano D., et al. VEGF el|Icits Epithelial-Mesenchymal Transition (EMT) in Prostate Intraepithelial Neoplasia (PIN)-Like Cells Via an Autocrine Loop. Experimental Cell Research. 2010;316;4:554-67. Doi: 10.1016/j.yexcr.2009.11.020.
60.Khromova N., Kopnin P., Rybko V., Kopnin B.P. Downregulation of VEGF-C Expression in Lung and Colon Cancer Cells Decelerates Tumor Growth and Inhibits Metastasis Via Multiple Mechanisms. Oncogene. 2012;31;11:1389-97. Doi: 10.1038/onc.2011.330.
61.Yi Z.Y., Feng L.J., Xiang Z., Yao H. Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma Cells. Journal of Investigative Surgery. 2011;24;2:67-76. Doi: 10.3109/08941939.2010.542272.
62.Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A., et al. Invasion and Metastasis in Colorectal Cancer: Epithelial-Mesenchymal Transition, Mesenchymal-Epithelial Transition, Stem Cells and Beta-Catenin. Cells, Tissues, Organs. 2005;179;1-2:56-65. Doi: 10.1159/000084509.
63.Ortensi B., Setti M., Osti D., Pelicci G. Cancer Stem Cell Contribution to Glioblastoma Invasiveness. Stem Cell Research & Therapy. 2013;4;1:18. Doi: 10.1186/scrt166.
64.Heldin C.H., Landstrom M., Moustakas A. Mechanism of TGF-Beta Signaling to Growth Arrest, Apoptosis, and Epithelial-Mesenchymal Transition. Current Opinion in Cell Biology. 2009;21;2:166-76. Doi: 10.1016/j.ceb.2009.01.021.
65.Mallini P., Lennard T., Kirby J., Meeson A. Epithelial-to-Mesenchymal Transition: what is the Impact on Breast Cancer Stem Cells and drug Resistance. Cancer Treatment Reviews. 2014;40;3:341-8. Doi: 10.1016/j.ctrv.2013.09.008.
66.Фармаковская М.Д., Хромова Н.В., Рыбко В.А., Копнин П.Б. Роль эпителиально-мезенхимального перехода в регуляции свойств раковых стволовых клеток солидных опухолей // Российский биотерапевтический журнал. 2015. Т.14. №4. С. 3-8 [Farmakovskaya M.D., Khromova N.V., Rybko V.A., Kopnin P.B. The Role of Epithelial-Mesenchymal Transition in Regulating the Properties of Cancer Stem Cells of Solid Tumors. Rossiyskiy Bioterapevticheskiy Zhurnal = Russian Journal of Biotherapeutics. 2015;14;4:3-8 (In Russ.)].
67.Kurrey N.K., Jalgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., et al. Snail and Slug Mediate Radioresistance and Chemoresistance by Antagonizing p53-Mediated Apoptosis and Acquiring a Stem-Like Phenotype in Ovarian Cancer Cells. Stem Cells. 2009;27;9:2059-68. Doi: 10.1002/stem.154.
68.Zhang X., Wu J., Luo S., Lechler T., Zhang J.Y. FRA1 Promotes Squamous Cell Carcinoma Growth and Metastasis through Distinct AKT and c-JUN Dependent Mechanisms. Oncotarget. 2016;7;23:34371-83. Doi: 10.18632/oncotarget.9110.
69.Diesch J., Sanij E., Gilan O., Love C., Tran H., Fleming N.I., et al. Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells. PloS One. 2014;9;3:e88950. Doi: 10.1371/journal.pone.0088950.
70.Zhang L., Liu H., Mu X., Cui J., Peng Z. Dysregulation of Fra1 Expression by Wnt/Beta-Catenin Signalling Promotes Glioma Aggressiveness through Epithelial-Mesenchymal Transition. Bioscience Reports. 2017;37;2:BSR20160643. Doi: 10.1042/BSR20160643.
71.Risolino M., Mandia N., Iavarone F., Dardaei L., Longobardi E., Fernandez S., et al. Transcription Factor PREP1 Induces EMT and Metastasis by Controlling the TGF-Beta-SMAD3 Pathway in Non-Small Cell Lung Adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2014;111;36:E3775-84. Doi: 10.1073/pnas.1407074111.
72.Usui A., Hoshino I., Akutsu Y., Sakata H., Nishimori T., Murakami K., et al. The Molecular Role of Fra-1 and its Prognostic Significance in Human Esophageal Squamous Cell Carcinoma. Cancer. 2012;118;13:3387-96. Doi: 10.1002/cncr.26652.
73.Lu D., Chen S., Tan X., Li N., Liu C., Li Z., et al. Fra-1 Promotes Breast Cancer Chemosensitivity by Driving Cancer Stem Cells from Dormancy. Cancer Research. 2012;72;14:3451-6. Doi: 10.1158/0008-5472.CAN-11-2536.
74.Sayan A.E., Stanford R., Vickery R., Grigorenko E., Diesch J., Kulbicki K., et al. Fra-1 Controls Motility of Bladder Cancer Cells via Transcriptional Upregulation of the Receptor Tyrosine Kinase AXL. Oncogene. 2012;31;12:1493-503. Doi: 10.1038/onc.2011.336.
75.Zhong G., Chen X., Fang X., Wang D., Xie M., Chen Q. Fra-1 is Upregulated in Lung Cancer Tissues and Inhibits the Apoptosis of Lung Cancer Cells by the P53 Signaling Pathway. Oncology Reports. 2016;35;1:447-53. Doi: 10.3892/or.2015.4395.
76.Gomez-Casal R., Bhattacharya C., Ganesh N., Bailey L., Basse P., Gibson M., et al. Non-Small Cell Lung Cancer Cells Survived Ionizing Radiation Treatment Display Cancer Stem Cell and Epithelial-Mesenchymal Transition Phenotypes. Molecular Cancer. 2013;12;1:94. Doi: 10.1186/1476-4598-12-94.
77.Siebzehnrubl F.A., Silver D.J., Tugertimur B., Deleyrolle L.P., Siebzehnrubl D., Sarkisian M.R., et al. The ZEB1 Pathway Links Glioblastoma Initiation, Invasion and Chemoresistance. EMBO Molecular Medicine. 2013;5;8:1196-212. Doi: 10.1002/emmm.201302827.
78.Plaks V., Kong N., Werb Z. The Cancer Stem Cell Niche: how Essential is the Niche in Regulating Stemness of Tumor Cells? Cell Stem Cell. 2015;16;3:225-38. Doi: 10.1016/j.stem.2015.02.015.
PDF (RUS) Полная версия статьи
Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.
Финансирование. Исследования выполнены при поддержке Российского научного фонда (проект № 24-45-20002, https://rscf.ru/project/24-45-20002/).
Участие авторов. Л. Алхаддад: сбор и анализ литературного материала, написание и редактирование текста; А.Н. Осипов и С.В. Леонов: разработка концепции и научное редактирование.
Поступила: 20.04.2026. Принята к публикации: 25.05.2026